Eculizumab for atypical hemolytic uremic syndrome in pregnancy

Gianluigi Ardissino, Manuela Wally Ossola, Giulia Maria Baffero, Angelo Rigotti, Massimo Cugno

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

Background: Atypical hemolytic uremic syndrome (HUS) is a thrombotic microangiopathy often caused by mutations in complement genes. During pregnancy, disease outcome is poor both for mother and fetus. Since 2009, the humanized monoclonal antibody eculizumab has been successfully used in the treatment of atypical HUS in nonpregnant patients. Case: A 26-year-old woman with a homozygous mutation in complement factor H developed a relapse of atypical HUS at 17 weeks of gestation in her first pregnancy. Because the disease remained active despite multiple plasma exchanges, eculizumab was started at 26 weeks of gestation. It was well tolerated and has led to remission and to the delivery of a healthy neonate. Conclusion: Eculizumab may be useful for the treatment of atypical HUS during pregnancy.

Original languageEnglish
Pages (from-to)487-489
Number of pages3
JournalObstetrics and Gynecology
Volume122
Issue number2 PART2
DOIs
Publication statusPublished - Aug 2013

Fingerprint

Pregnancy
Thrombotic Microangiopathies
faropenem medoxomil
Complement Factor H
Antibodies, Monoclonal, Humanized
Mutation
Plasma Exchange
Fetus
Mothers
Atypical Hemolytic Uremic Syndrome
eculizumab
Newborn Infant
Recurrence
Therapeutics
Genes

ASJC Scopus subject areas

  • Obstetrics and Gynaecology

Cite this

Eculizumab for atypical hemolytic uremic syndrome in pregnancy. / Ardissino, Gianluigi; Ossola, Manuela Wally; Baffero, Giulia Maria; Rigotti, Angelo; Cugno, Massimo.

In: Obstetrics and Gynecology, Vol. 122, No. 2 PART2, 08.2013, p. 487-489.

Research output: Contribution to journalArticle

@article{a08b39c96919451d9f6d233ad7dc2473,
title = "Eculizumab for atypical hemolytic uremic syndrome in pregnancy",
abstract = "Background: Atypical hemolytic uremic syndrome (HUS) is a thrombotic microangiopathy often caused by mutations in complement genes. During pregnancy, disease outcome is poor both for mother and fetus. Since 2009, the humanized monoclonal antibody eculizumab has been successfully used in the treatment of atypical HUS in nonpregnant patients. Case: A 26-year-old woman with a homozygous mutation in complement factor H developed a relapse of atypical HUS at 17 weeks of gestation in her first pregnancy. Because the disease remained active despite multiple plasma exchanges, eculizumab was started at 26 weeks of gestation. It was well tolerated and has led to remission and to the delivery of a healthy neonate. Conclusion: Eculizumab may be useful for the treatment of atypical HUS during pregnancy.",
author = "Gianluigi Ardissino and Ossola, {Manuela Wally} and Baffero, {Giulia Maria} and Angelo Rigotti and Massimo Cugno",
year = "2013",
month = "8",
doi = "10.1097/AOG.0b013e31828e2612",
language = "English",
volume = "122",
pages = "487--489",
journal = "Obstetrics and Gynecology",
issn = "0029-7844",
publisher = "Lippincott Williams and Wilkins",
number = "2 PART2",

}

TY - JOUR

T1 - Eculizumab for atypical hemolytic uremic syndrome in pregnancy

AU - Ardissino, Gianluigi

AU - Ossola, Manuela Wally

AU - Baffero, Giulia Maria

AU - Rigotti, Angelo

AU - Cugno, Massimo

PY - 2013/8

Y1 - 2013/8

N2 - Background: Atypical hemolytic uremic syndrome (HUS) is a thrombotic microangiopathy often caused by mutations in complement genes. During pregnancy, disease outcome is poor both for mother and fetus. Since 2009, the humanized monoclonal antibody eculizumab has been successfully used in the treatment of atypical HUS in nonpregnant patients. Case: A 26-year-old woman with a homozygous mutation in complement factor H developed a relapse of atypical HUS at 17 weeks of gestation in her first pregnancy. Because the disease remained active despite multiple plasma exchanges, eculizumab was started at 26 weeks of gestation. It was well tolerated and has led to remission and to the delivery of a healthy neonate. Conclusion: Eculizumab may be useful for the treatment of atypical HUS during pregnancy.

AB - Background: Atypical hemolytic uremic syndrome (HUS) is a thrombotic microangiopathy often caused by mutations in complement genes. During pregnancy, disease outcome is poor both for mother and fetus. Since 2009, the humanized monoclonal antibody eculizumab has been successfully used in the treatment of atypical HUS in nonpregnant patients. Case: A 26-year-old woman with a homozygous mutation in complement factor H developed a relapse of atypical HUS at 17 weeks of gestation in her first pregnancy. Because the disease remained active despite multiple plasma exchanges, eculizumab was started at 26 weeks of gestation. It was well tolerated and has led to remission and to the delivery of a healthy neonate. Conclusion: Eculizumab may be useful for the treatment of atypical HUS during pregnancy.

UR - http://www.scopus.com/inward/record.url?scp=84880958391&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880958391&partnerID=8YFLogxK

U2 - 10.1097/AOG.0b013e31828e2612

DO - 10.1097/AOG.0b013e31828e2612

M3 - Article

C2 - 23884270

AN - SCOPUS:84880958391

VL - 122

SP - 487

EP - 489

JO - Obstetrics and Gynecology

JF - Obstetrics and Gynecology

SN - 0029-7844

IS - 2 PART2

ER -